Status:
COMPLETED
Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
Lead Sponsor:
BioInvent International AB
Collaborating Sponsors:
Oxurion
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tum...
Eligibility Criteria
Inclusion
- Confirmed malignity
- Measurable disease
- Performance status 1 or less (ECOG)
Exclusion
- Acute illness or infection
- Concurrent second malignancy
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00702494
Start Date
June 1 2008
End Date
September 1 2009
Last Update
March 16 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Onkologisk Klinik 5072 Finsencentret Rigshospitalet
Copenhagen, Denmark, DK-2100
2
Onkologisk Afdeling 54B1 Herlev Hospital
Herlev, Denmark, DK-2730